Hexarelin (Examorelin)
In 12 healthy men, mean peak GH was 3.9 ng/mL after placebo (PMID 7957536; checked 24 Aug 2026). At the highest test level, it was 55.0 ng/mL. The double-blind study found a level-related response. These results belong to Hexarelin, not GHRP-6.
Which names and codes belong to Hexarelin?
GSRS shows the INN EXAMORELIN and the name HEXARELIN (GSRS; checked 24 Aug 2026). It gives UNII 09QF37C617 and CAS 140703-51-1.
GSRS also lists the project codes EP-23905 and MF-6003 (checked 24 Aug 2026).
Hexarelin is a GHRP-6 analogue with its own codes and human studies. A factual link does not move evidence between them.
What did the double-blind 12-person study measure?
Twelve men took placebo and three rising test levels (PMID 7957536; checked 24 Aug 2026). Placebo appeared at a random point in the order.
| Study level | Mean peak GH | Primary source |
|---|---|---|
| Placebo | 3.9 ng/mL | PMID 7957536 |
| Low | 26.9 ng/mL | PMID 7957536 |
| Middle | 52.3 ng/mL | PMID 7957536 |
| High | 55.0 ng/mL | PMID 7957536 |
GH peaked at about 30 minutes. It returned to baseline within 240 minutes. The reported GH fall had a half-life of about 55 minutes.
PubMed marks non-US government support. It gives no grant code. The listed affiliation is Mediolanum Farmaceutici. Funding in the full paper was not checked.
What did the short heart study find?
PMID 10528131 studied seven GH-deficient men and nine male controls (checked 24 Aug 2026).
| Group | LVEF at baseline | Peak LVEF after Hexarelin |
|---|---|---|
| GH-deficient men | 50 ± 1% | 57 ± 2% |
| Controls | 63 ± 2% | 70 ± 2% |
Both LVEF rises had p < 0.05 versus baseline. The abstract reports no change in mean blood pressure, catecholamines, or cardiac output.
The GH peak was 1.9 ± 0.9 µg/L in the deficient group. It was 45.7 ± 3.6 µg/L in controls (p < 0.001). The heart result was acute. The study did not measure a clinical outcome.
PubMed marks non-US government support. It gives no grant code. Funding in the full paper was not checked.
What did the controlled sleep study find?
Seven young healthy people got Hexarelin or placebo during the night (PMID 15177700; checked 24 Aug 2026).
Stage 4 sleep fell during the first half of the night. EEG delta power fell across the night. GH and prolactin rose across the night. ACTH and cortisol rose during the first half.
Leptin and the measured TNF markers did not change. The authors said sleep may be worse.
PubMed marks non-US government support. It gives no grant code. Funding in the full paper was not checked.
What safety information do the accessible records provide?
PubMed cuts off the dose-response abstract. The visible text has no full adverse-event table (PMID 7957536; checked 24 Aug 2026). The heart record indexes drug-caused flushing. Its abstract gives no count, length, or severity.
The sleep study found less stage 4 sleep and lower delta power. None of these papers reports long-term results.
ClinicalTrials.gov lists no study under either exact name.
What does evidence tier B mean here?
Controlled human studies measured GH, short-term heart function, and sleep. Tier B stays right for Hexarelin (checked 24 Aug 2026).
The tier belongs to Hexarelin. It does not come from GHRP-6.
What is the recorded EU status?
The EU Commission index has no exact entry for Hexarelin or Examorelin (Union Register index; checked 24 Aug 2026). The EU field stays unclear.
Why is the first-observed field 2011-02?
PMID 21298258 came out online on 6 February 2011 (checked 24 Aug 2026). The testing paper names Hexarelin among drugs targeted by urine tests. It says their misuse remained unrecognized.
This supports 2011-02 as the date of a paper about current misuse. It is not a product seizure or sale date.
What does this register entry cover?
This entry covers Hexarelin and these human studies. It does not cover GHRP-6.
→ GHRP-6 register entry → What can be in a vial → All register entries